InMode’s Revenue Guidance Revised Amid Economic Slowdown and Financing Constraints

1 Mins read

Shares of InMode have taken a hit as the company revises its full-year revenue guidance in response to current economic conditions and increasing limitations on financing. This downturn has resulted in a 14% decline in the stock, currently trading at $24.14. Over the course of the year, shares have already fallen by 22%.

The medical technology company, based in Israel, announced on Thursday that it now predicts its revenue for 2023 to be between $500 million and $510 million. This represents a decline from its previous estimate of $530 million to $540 million.

Furthermore, InMode anticipates third-quarter earnings to range from 59 cents to 60 cents per share, with sales totaling $122.8 million to $123 million. Both figures are expected to fall short of analyst forecasts.

The revised outlook is attributed to delayed purchasing decisions during the third quarter, largely influenced by decreased aesthetic activity over the summer months. In addition, InMode is grappling with financing constraints in the realm of medical equipment, which has negatively impacted its sales activity.

Overall, the company is navigating through challenging circumstances, necessitating revisions to its projections.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

+ 59 = 69